Table 2.
Comparison of characteristics of patients with bronchiectasis versus nonbronchiectasis
| Variables | Nonbronchiectasis group (n = 104) | Bronchiectasis group (n = 72) | P Value |
|---|---|---|---|
| Male sex, n (%) | 51 (49.04) | 38 (52.78) | 0.626 |
| Age, y | 53.28 ± 14.66 (50.43–56.13) | 54.81 ± 13.71 (51.58–58.03) | 0.487 |
| BMI, kg/m2 | 24.87 ± 3.61 (24.17–25.57) | 24.12 ± 4.37 (23.09–25.14) | 0.213 |
| Positive smoking statusa, n (%) | 31 (29.81) | 24 (33.33) | 0.620 |
| Smoking indexb, pack-years | 10.00 (8.00,14.00) | 8.00 (6.25,13.50) | 0.113 |
| Duration of asthma, y | 5.50 (1,12.75) | 8.00 (2.00, 20.00) | 0.171 |
| NPs, n (%) | 35 (33.65) | 40 (55.56) | 0.004 |
| Prior sinus surgery, n (%) | 16 (15.38) | 18 (25.00) | 0.112 |
| Allergic rhinitis, n (%) | 63 (60.58) | 49 (68.06) | 0.311 |
| Atopic dermatitis, n (%) | 11 (10.58) | 3 (4.17) | 0.122 |
| Gastroesophageal reflux disease, n (%) | 9 (8.65) | 5 (6.94) | 0.680 |
| ICS dose (fluticasone equivalent), μg/d | 320.00 (160.00, 320.00) | 285.00 (160.00, 320.00) | 0.713 |
| Severe asthma, n (%) | 11 (10.58) | 15 (20.83) | 0.059 |
| ≥ 1 severe exacerbation of asthma in the last 12 months, n (%) | 23 (22.12) | 31 (43.06) | 0.003 |
| ≥ 1 pneumonia in the last 12 months, n (%) | 27 (25.96) | 24 (33.33) | 0.289 |
| Peripheral blood eosinophil counts, × 109/L | 0.32 (0.15, 0.58) | 0.44 (0.23, 0.90) | 0.022 |
| FeNO, ppb | 32.00 (18.00, 61.75) | 44.00 (23.00,74.75) | 0.056 |
| Total IgE, IU/mL | 135.50 (48.10, 285.50) | 232.00 (56.75,525.25) | 0.044 |
| Atopy, n (%) | 57 (54.81) | 34 (47.22) | 0.322 |
| Postbronchodilator FEV1% predicted, % | 83.09 ± 16.47 (79.89–86.30) | 73.32 ± 22.94 (67.93–78.71) | 0.006 |
| LM scores | 9.00 (6.00, 15.75) | 11.50 (7.25, 18.00) | 0.044 |
| Smith scores of bronchiectasis | 7.56 ± 3.46 (6.75–8.37) | ||
| Bhalla scores of bronchiectasis | 3.97 ± 1.50 (3.62–4.32) |
Parametric data are expressed as the mean ± SD (95% CI); nonparametric data are expressed as the median (interquartile range)
BMI body mass index, NPs nasal polyps, FEV1 forced expiratory volume in 1 s, ICS inhaled corticosteroid, FeNO fractional exhaled nitric oxide, IgE immunoglobulin E, LM Lund-Mackay
aPositive smoking status included ex- and current smokers
bSmoking history in patients with positive smoking status